Craig Hallum Boosts BioLife Solutions (NASDAQ:BLFS) Price Target to $30.00

BioLife Solutions (NASDAQ:BLFS) had its price objective increased by Craig Hallum from $23.00 to $30.00 in a research report report published on Monday morning, Benzinga reports. The firm currently has a buy rating on the medical equipment provider’s stock.

BLFS has been the topic of several other reports. Northland Securities raised their price target on BioLife Solutions from $26.00 to $28.00 and gave the stock an outperform rating in a research report on Friday, August 9th. Benchmark raised shares of BioLife Solutions from a neutral rating to a buy rating and set a $25.00 price target for the company in a research report on Monday, May 13th. TD Cowen boosted their price objective on shares of BioLife Solutions from $20.00 to $26.00 and gave the company a buy rating in a research report on Wednesday, July 17th. Finally, StockNews.com upgraded BioLife Solutions to a sell rating in a report on Friday, May 10th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and an average target price of $26.20.

BioLife Solutions Price Performance

Shares of NASDAQ:BLFS opened at $25.90 on Monday. The company’s fifty day moving average price is $21.80 and its 200-day moving average price is $19.57. BioLife Solutions has a one year low of $8.92 and a one year high of $26.73. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.89 and a quick ratio of 1.77. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -18.24 and a beta of 1.85.

Insider Transactions at BioLife Solutions

In other news, insider Sarah Aebersold sold 3,000 shares of BioLife Solutions stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $21.03, for a total value of $63,090.00. Following the completion of the transaction, the insider now owns 61,683 shares of the company’s stock, valued at approximately $1,297,193.49. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, insider Sarah Aebersold sold 3,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $21.03, for a total transaction of $63,090.00. Following the sale, the insider now directly owns 61,683 shares of the company’s stock, valued at $1,297,193.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CMO Todd Berard sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $20.18, for a total transaction of $201,800.00. Following the completion of the sale, the chief marketing officer now owns 108,894 shares in the company, valued at approximately $2,197,480.92. The disclosure for this sale can be found here. Insiders have sold 15,215 shares of company stock valued at $313,281 in the last three months. 2.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BioLife Solutions

Institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC bought a new position in shares of BioLife Solutions during the 2nd quarter valued at about $1,041,000. Fred Alger Management LLC raised its stake in BioLife Solutions by 6.0% during the second quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock valued at $33,841,000 after purchasing an additional 88,840 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of BioLife Solutions in the second quarter valued at $229,000. Public Sector Pension Investment Board raised its stake in shares of BioLife Solutions by 11.0% in the second quarter. Public Sector Pension Investment Board now owns 79,987 shares of the medical equipment provider’s stock valued at $1,714,000 after acquiring an additional 7,902 shares during the period. Finally, Sei Investments Co. raised its stake in shares of BioLife Solutions by 100.1% in the second quarter. Sei Investments Co. now owns 120,418 shares of the medical equipment provider’s stock valued at $2,581,000 after acquiring an additional 60,227 shares during the period. Hedge funds and other institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.